NCT02944006

Brief Summary

This study aims to establish radiomics database for pancreas cancer from multiparametric MRI including DCE-MRI obtained by using incoherent undersampling and radial acquisition for clinical staging as well as quantitative analysis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
29

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 24, 2016

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 25, 2016

Completed
1 month until next milestone

Study Start

First participant enrolled

November 28, 2016

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2023

Completed
Last Updated

December 17, 2021

Status Verified

December 1, 2021

Enrollment Period

6 years

First QC Date

October 24, 2016

Last Update Submit

December 16, 2021

Conditions

Keywords

MRI

Outcome Measures

Primary Outcomes (1)

  • T-staging

    T-staging of the tumor at MRI.

    4 weeks after MR acquisition

Secondary Outcomes (10)

  • N-staging

    4 weeks after MR acquisition

  • arterial blood flow

    4 weeks after MR acquisition

  • arterial fraction

    4 weeks after MR acquisition

  • mean transit time

    4 weeks after MR acquisition

  • extracellular volume

    4 weeks after MR acquisition

  • +5 more secondary outcomes

Other Outcomes (7)

  • T1 value

    4 weeks after MR acquisition

  • T2 value

    4 weeks after MR acquisition

  • fat fraction

    4 weeks after MR acquisition

  • +4 more other outcomes

Interventions

multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who are scheduled to undergo pancreatobiliary MRI as a preoperative workup for suspected resectable pancreas cancer (adenocarcinoma)

You may qualify if:

  • surgical candidate for pancreatico-duodenectomy
  • characteristic finding of pancreatic adenocarcinoma on prior CT or MRI
  • OR histologically diagnosed with pancreatic adenocarcinoma
  • signed for informed consent

You may not qualify if:

  • under 18 years
  • not eligible for pancreatico-duodenectomy
  • unresectable patients (locally advanced on prior CT/MRI or metastatic disease)
  • tumors with suspicion of other histologic types (neuroendocrine, IPMN, etc)
  • any contra-indication of contrast-enhanced MRI
  • recurred pancreatic cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Officials

  • Jeong Min Lee, MD

    Seoul National University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 24, 2016

First Posted

October 25, 2016

Study Start

November 28, 2016

Primary Completion

December 1, 2022

Study Completion

November 1, 2023

Last Updated

December 17, 2021

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share

Locations